Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03618550 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
A Phase 2 study of Hodgkin Lymphoma and Relapsed or Refractory Hodgkin Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 257
- Enrollment target
- 8
- Study locations
NCT03618550: Recruiting Phase 2 study of Hodgkin Lymphoma and Relapsed or Refractory Hodgkin Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03618550 is a Phase 2 study of Hodgkin Lymphoma and Relapsed or Refractory Hodgkin Lymphoma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 257 participants, above the 162-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (59% higher). The trial reports 8 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03618550, a Phase 2 study of Hodgkin Lymphoma and Relapsed or Refractory Hodgkin Lymphoma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 257 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma.
Primary Outcome
Response to pembrolizumab-GVD will be assessed using the RECIL criteria.
Conditions Studied
Interventions
- DRUG pembrolizumab
- DRUG gemcitabine
- DRUG vinorelbine
- DRUG liposomal doxorubicin
- PROCEDURE Stem cell mobilization and collection
Study Locations (8)
New York
- Memorial Sloan Kettering Cancer Center @ Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 257 participants |
| Start Date | 2018-08-01 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
What NCT03618550 shows while recruiting
NCT03618550 is an interventional study that assigns participants to a tested intervention. The registered 257 participants enrollment target is mid-sized for trials with a published cap, above the 162-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (59% higher).
The record links to 2 conditions, with Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which pembrolizumab is the first listed.
NCT03618550 lists 8 locations in 3 states (New York, New Jersey, Florida).
Frequently Asked Questions
What is clinical trial NCT03618550 about?
NCT03618550 is a clinical study titled "Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma". The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma.
What is the current status of trial NCT03618550?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 257 participants. The study started on 2018-08-01. Estimated completion is 2026-08.
What conditions does trial NCT03618550 study?
This clinical trial studies the following conditions: Hodgkin Lymphoma, Relapsed or Refractory Hodgkin Lymphoma.
What interventions are being tested in trial NCT03618550?
The interventions under investigation include: pembrolizumab (DRUG), gemcitabine (DRUG), vinorelbine (DRUG), liposomal doxorubicin (DRUG), Stem cell mobilization and collection (PROCEDURE).
Who is sponsoring clinical trial NCT03618550?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03618550 being conducted?
This trial has 8 study locations across Florida, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03618550's enrollment target sits among peer trials
257 10th of 71 higher than 62 of 71 other Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
RECRUITING · Phase 2
-
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
RECRUITING · Phase 2
-
BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma
RECRUITING · Phase 2
-
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
RECRUITING · Phase 2
-
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
RECRUITING · Phase 2
-
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04674267 · 257 participants · NA
Resilience and Equity in Aging, Cancer, and Health (REACH)
- NCT06099288 · 257 participants · NA
Strong Families Start at Home/Familias Fuertes Comienzan en Casa
- NCT06207084 · 257 participants · NA
The Fit With Us Study
- NCT03785288 · 258 participants · Phase 3
Vaginal Cuff Brachytherapy Fractionation Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI